High incidence of trastuzumab induced cardiotoxicity among HER2 positive breast cancer patients: a Brazilian retrospective study

• In: Posters
• At: Dublin (Ireland) (2013)
• Type: Poster
• By: ROCHA AYRES, Lorena (Faculdade de Ciências Farmacêuticas de Ribeirão Preto - FCFRP/USP, Ciências Farmacêuticas, Ribeirão Preto, Brazil)
• Co-author(s): Silveira de Almeida Campos, Marília (Faculdade de Ciências Farmacêuticas de Ribeirão Preto - FCFRP/USP, Ribeirão Preto, Brazil)
  De Oliveira Gozzo, Thais (Escola de Enfermagem de Ribeirão Preto - Universidade de São Paulo - EERP/USP, Ribeirão Preto, Brazil)
  Ungari, Andrea (Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto - HCFMRP/USP, Ribeirão Preto, Brazil)
  Moreira de Andrade, Jurandyr (Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto - HCFMRP/USP, Ribeirão Preto, Brazil)
  Régis Leira Pereira, Leonardo (Faculdade de Ciências Farmacêuticas de Ribeirão Preto - FCFRP/USP, Ribeirão Preto, Brazil)
  
• Abstract:

  
  Background:
  The monoclonal antibody trastuzumab is associated with a reduced risk of recurrence and increased survival in HER2 positive breast cancer patients. Although generally well tolerated, trastuzumab may cause cardiotoxicity, leading to treatment discontinuation, which can deprive patients of the benefits of this therapy.
  Aim:
  Therefore,
  
  ..

The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress. Please login